This biologic Ustekinumab was recently approved by the FDA for Crohn's - the stats on responders/remission are interesting to compare to Rem-L
So here they chose 628 patients who had failed to respond to conventional treatment, of those 397 responded to Ustekinumab and of those say 400 who responded approx 50% of them were in remission at 44 weeks - so your total numbers for remission are 200/628 or well less than 30%.
https://www.nejm.org/doi/full/10.1056/nejmoa1602773
oh and if you're interested have a look at the side effects profiles of the current treatments - most of these are immunosuppressants meaning you're at risk of TB or sepsis at best at worst increasing risk of serious cancers
https://www.webmd.com/ibd-crohns-disease/crohns-disease/crohns-biologics
- Forums
- ASX - By Stock
- Crohn’s Disease
This biologic Ustekinumab was recently approved by the FDA for...
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 27197 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 43578 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 31763 | 1.100 |
2 | 33264 | 1.090 |
2 | 18897 | 1.085 |
2 | 18926 | 1.080 |
1 | 18000 | 1.075 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 23400 | 3 |
1.135 | 1090 | 1 |
1.140 | 65000 | 4 |
1.145 | 64500 | 3 |
1.150 | 92314 | 9 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |